Accès libre

Antibiotic Resistance Among Uropathogenic Escherichia coli

BARBARA KOT

BARBARA KOT

Department of Microbiology, Faculty of Natural Sciences, Siedlce University of Natural Sciences and HumanitiesSiedlce, Poland
Recherchez cet auteur sur
Sciendo|Google Scholar
KOT, BARBARA
  
05 déc. 2019
Antibiotic Resistance Among Uropathogenic Escherichia coli's Cover Image
À propos de cet article
Article précédent
Article suivant
Citez
Télécharger la couverture
Catégorie d'article: mini-review
Publié en ligne: 05 déc. 2019
Pages: 403 - 415
Reçu: 30 juin 2019
Accepté: 24 sept. 2019
DOI: https://doi.org/10.33073/pjm-2019-048
Mots clés
© 2019 Barbara Kot et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Fig. 1.

Classification of urinary tract infections (Bartoletti et al. 2016).
Classification of urinary tract infections (Bartoletti et al. 2016).

Fig. 2.

The resistance of UPEC to antimicrobials using in the treatment of UTIs.Amoxicillin-clavulanic acid; the developed countries (USA, 3.1–40%; Germany, 5.3%; Poland, 13.9%; England, 30%; France, 37.6%), developing countries (Nepal, 48%; Pakistan, 71%; Jordan, 83%). Ciprofloxacin; developed countries (USA, 5.1–12.1%; Belgium, 12.9%; Germany, 10.5–17.3%; Switzerland.17.4%; England, 20.4%; France, 24.8%; Spain, 39.8%), developing countries (Jordan, 55.5%, Mongolia, 58.1%; Pakistan, 60.8%; Nepal, 64.6%; Ethiopia, 85.5%). Trimethoprim-sulfamethoxazole; developed countries (Belgium, 14.6%; USA, 17.4%; Germany, 18.45%; Poland, 21.4%; Switzerland, 24.5%; Spain, 30.9%; France, 37.1%), developing countries (Iran, 54%; Mexico, 66%; Ethiopia, 68.5%; Mongolia, 70.9%; Jordan, 73,1%; Pakistan, 82%).
The resistance of UPEC to antimicrobials using in the treatment of UTIs.Amoxicillin-clavulanic acid; the developed countries (USA, 3.1–40%; Germany, 5.3%; Poland, 13.9%; England, 30%; France, 37.6%), developing countries (Nepal, 48%; Pakistan, 71%; Jordan, 83%). Ciprofloxacin; developed countries (USA, 5.1–12.1%; Belgium, 12.9%; Germany, 10.5–17.3%; Switzerland.17.4%; England, 20.4%; France, 24.8%; Spain, 39.8%), developing countries (Jordan, 55.5%, Mongolia, 58.1%; Pakistan, 60.8%; Nepal, 64.6%; Ethiopia, 85.5%). Trimethoprim-sulfamethoxazole; developed countries (Belgium, 14.6%; USA, 17.4%; Germany, 18.45%; Poland, 21.4%; Switzerland, 24.5%; Spain, 30.9%; France, 37.1%), developing countries (Iran, 54%; Mexico, 66%; Ethiopia, 68.5%; Mongolia, 70.9%; Jordan, 73,1%; Pakistan, 82%).
Langue:
Anglais
Périodicité:
4 fois par an
Sujets de la revue:
Sciences de la vie, Microbiologie et virologie
RSS Feed de la revue